These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Antiangiogenic therapy in the management of brain tumors: a clinical overview. Kunnakkat S; Mathew M; Narayana A Cancer Chemother Pharmacol; 2012 Sep; 70(3):353-63. PubMed ID: 22825032 [TBL] [Abstract][Full Text] [Related]
26. Circulating endothelial cells as biomarkers in clinical oncology. Mancuso P; Bertolini F Microvasc Res; 2010 May; 79(3):224-8. PubMed ID: 20176038 [TBL] [Abstract][Full Text] [Related]
28. Metronomic dosing of chemotherapy: applications in pediatric oncology. Stempak D; Seely D; Baruchel S Cancer Invest; 2006; 24(4):432-43. PubMed ID: 16777697 [TBL] [Abstract][Full Text] [Related]
29. Escape mechanisms after antiangiogenic treatment, or why are the tumors growing again? Hlushchuk R; Makanya AN; Djonov V Int J Dev Biol; 2011; 55(4-5):563-7. PubMed ID: 21858777 [TBL] [Abstract][Full Text] [Related]
30. Antiangiogenesis, anti-VEGF(R) and outlook. Petersen I Recent Results Cancer Res; 2007; 176():189-99. PubMed ID: 17607926 [TBL] [Abstract][Full Text] [Related]
32. Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy. Pasqualetti G; Danesi R; Del Tacca M; Bocci G Pharmacogenomics; 2007 Jan; 8(1):49-66. PubMed ID: 17187509 [TBL] [Abstract][Full Text] [Related]
33. Molecular markers to predict outcome to antiangiogenic therapies in colorectal cancer: current evidence and future perspectives. Custodio A; Barriuso J; de Castro J; Martínez-Marín V; Moreno V; Rodríguez-Salas N; Feliu J Cancer Treat Rev; 2013 Dec; 39(8):908-24. PubMed ID: 23510598 [TBL] [Abstract][Full Text] [Related]
34. Anti-angiogenic therapy, a new player in the field of sarcoma treatment. Versleijen-Jonkers YM; Vlenterie M; van de Luijtgaarden AC; van der Graaf WT Crit Rev Oncol Hematol; 2014 Aug; 91(2):172-85. PubMed ID: 24613529 [TBL] [Abstract][Full Text] [Related]
35. Current data on predictive markers for anti-angiogenic therapy in thoracic tumours. Reinmuth N; Thomas M; Meister M; Schnabel PA; Kreuter M Eur Respir J; 2010 Oct; 36(4):915-24. PubMed ID: 20889462 [TBL] [Abstract][Full Text] [Related]
36. Antiangiogenic therapies: going beyond their limits. Moserle L; Jiménez-Valerio G; Casanovas O Cancer Discov; 2014 Jan; 4(1):31-41. PubMed ID: 24356098 [TBL] [Abstract][Full Text] [Related]
37. Molecular mechanisms of hypertension and heart failure due to antiangiogenic cancer therapies. Rees ML; Khakoo AY Heart Fail Clin; 2011 Jul; 7(3):299-311. PubMed ID: 21749882 [TBL] [Abstract][Full Text] [Related]
38. Interleukin-6: an angiogenic target in solid tumours. Middleton K; Jones J; Lwin Z; Coward JI Crit Rev Oncol Hematol; 2014 Jan; 89(1):129-39. PubMed ID: 24029605 [TBL] [Abstract][Full Text] [Related]
40. Circulating endothelial cells and their subpopulations: role as predictive biomarkers in antiangiogenic therapy for colorectal cancer. Manzoni M; Comolli G; Torchio M; Mazzini G; Danova M Clin Colorectal Cancer; 2015 Mar; 14(1):11-7. PubMed ID: 25591800 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]